Genta's CLL Data Better; Don't Count Them Out'
By Randall Osborne
Tuesday, September 20, 2005
Genta Inc.'s ongoing bid to find a replacement partner for Genasense can only be helped by more positive news from its Phase III study testing the compound with chemotherapy against relapsed or refractory chronic lymphocytic leukemia. (BioWorld Today)
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.